Efficacy and Safety of Heterologous Booster Vaccination After Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study

Overview

Journal Vaccines (Basel)

Date 2022 Mar 26

PMID 35335032

Authors

Jose Francisco Munoz-Valle

Gabriela Athziri Sanchez-Zuno

Monica Guadalupe Matuz-Flores

Cristian Oswaldo Hernandez-Ramirez

Saul Alberto Diaz-Perez

Christian Johana Banos-Hernandez

Francisco Javier Turrubiates-Hernandez

Alejandra Natali Vega-Magana

Jorge Hernandez-Bello

Affiliations

Soon will be listed here.

Abstract

Several studies have reported the benefits and safety of heterologous vaccination among different approved vaccines; however, there are no specific reports on the effects of vaccination with the Ad5-nCoV and other vaccines of the same or different technologies. In the present study, we evaluated the neutralizing antibodies percentage against SARS-CoV-2 in Mexican patients immunized with the Ad5-nCoV vaccine six months after its application. Moreover, the effect of the heterologous vaccination with the Ad5-nCoV vaccine and a booster dose of ChAdOx1-S-Nov-19, Ad26.COV2.S, BNT162b2, or mRNA-127 were determined. Our results suggest that a heterologous regimen of one dose with Ad5-nCoV vaccine followed by a booster dose of a different vaccine is safe and induces a stronger humoral immune response.

Citing Articles

Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population.

Hernandez-Bello J, Lorenzo-Leal A, Munoz-Valle J, Morales-Nunez J, Diaz-Perez S, Hernandez-Gutierrez R PLoS One. 2024; 19(4):e0299520.

PMID: 38573914 PMC: 10994301. DOI: 10.1371/journal.pone.0299520.

Evaluation of SARS-CoV-2 infection risks after primary vaccination with BNT162b2, BBIBP-CorV, or ChAdOx1-nCOV-19 and after homologous and heterologous booster vaccinations with these vaccines and evaluation of SARS-CoV-2 reinfection profiles.

Djorwe S, Bousfiha A, Nzoyikorera N, Nyandwi J, Kawthar B, Malki A Biomedicine (Taipei). 2023; 13(3):31-48.

PMID: 37937059 PMC: 10627210. DOI: 10.37796/2211-8039.1412.

References

Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D . Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10318):2258-2276. PMC: 8639161. DOI: 10.1016/S0140-6736(21)02717-3. View

Dolgin E . Omicron is supercharging the COVID vaccine booster debate. Nature. 2021; . DOI: 10.1038/d41586-021-03592-2. View

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

Sapkota B, Saud B, Shrestha R, Al-Fahad D, Sah R, Shrestha S . Heterologous prime-boost strategies for COVID-19 vaccines. J Travel Med. 2021; 29(3). PMC: 8754745. DOI: 10.1093/jtm/taab191. View

Pozzetto B, Legros V, Djebali S, Barateau V, Guibert N, Villard M . Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Nature. 2021; 600(7890):701-706. DOI: 10.1038/s41586-021-04120-y. View

Rosete D, Manjarrez M, Barron B . Adenoviruses C in non-hospitalized Mexican children older than five years of age with acute respiratory infection. Mem Inst Oswaldo Cruz. 2008; 103(2):195-200. DOI: 10.1590/s0074-02762008000200012. View

Hernandez-Bello J, Morales-Nunez J, Machado-Sulbaran A, Diaz-Perez S, Torres-Hernandez P, Balcazar-Felix P . Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2. Vaccines (Basel). 2021; 9(9). PMC: 8472849. DOI: 10.3390/vaccines9091047. View

Hotez P, Batista C, Ben Amor Y, Ergonul O, Figueroa J, Gilbert S . Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic. EClinicalMedicine. 2021; 39:101053. PMC: 8330385. DOI: 10.1016/j.eclinm.2021.101053. View

Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S . Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021; 27(9):1530-1535. PMC: 8440177. DOI: 10.1038/s41591-021-01464-w. View

10.

Halperin S, Ye L, MacKinnon-Cameron D, Smith B, Cahn P, Ruiz-Palacios G . Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded,.... Lancet. 2021; 399(10321):237-248. PMC: 8700283. DOI: 10.1016/S0140-6736(21)02753-7. View

11.

Kennedy R . Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine. Lancet. 2021; 399(10321):212-213. PMC: 8700275. DOI: 10.1016/S0140-6736(21)02834-8. View

12.

Zhu F, Li Y, Guan X, Hou L, Wang W, Li J . Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; 395(10240):1845-1854. PMC: 7255193. DOI: 10.1016/S0140-6736(20)31208-3. View

13.

Daian E Silva D, Guimaraes da Fonseca F . The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis. Vaccines (Basel). 2021; 9(10). PMC: 8538930. DOI: 10.3390/vaccines9101101. View

14.

Sanchez-Zuno G, Matuz-Flores M, Gonzalez-Estevez G, Nicoletti F, Turrubiates-Hernandez F, Mangano K . A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies. Int J Immunopathol Pharmacol. 2021; 35:20587384211050199. PMC: 8512237. DOI: 10.1177/20587384211050199. View

15.

Sprent J, King C . COVID-19 vaccine side effects: The positives about feeling bad. Sci Immunol. 2021; 6(60). PMC: 9267253. DOI: 10.1126/sciimmunol.abj9256. View

16.

Godeau D, Petit A, Richard I, Roquelaure Y, Descatha A . Return-to-work, disabilities and occupational health in the age of COVID-19. Scand J Work Environ Health. 2021; 47(5):408-409. PMC: 8259700. DOI: 10.5271/sjweh.3960. View

17.

Borobia A, Carcas A, Perez-Olmeda M, Castano L, Bertran M, Garcia-Perez J . Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10295):121-130. PMC: 8233007. DOI: 10.1016/S0140-6736(21)01420-3. View

18.

Liu Y, Liu J, Xia H, Zhang X, Fontes-Garfias C, Swanson K . Neutralizing Activity of BNT162b2-Elicited Serum. N Engl J Med. 2021; 384(15):1466-1468. PMC: 7944950. DOI: 10.1056/NEJMc2102017. View

19.

Nordstrom P, Ballin M, Nordstrom A . Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. Lancet Reg Health Eur. 2021; 11:100249. PMC: 8520818. DOI: 10.1016/j.lanepe.2021.100249. View

20.

Romero-Ibarguengoitia M, Rivera-Salinas D, Hernandez-Ruiz Y, Armendariz-Vazquez A, Gonzalez-Cantu A, Barco-Flores I . Effect of Heterologous Vaccination Regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG Antibodies Titers. Vaccines (Basel). 2022; 10(3). PMC: 8948699. DOI: 10.3390/vaccines10030392. View